Form 8-K

8-K — NutriBand Inc.

Accession: 0001213900-26-041006

Filed: 2026-04-07

Period: 2026-03-30

CIK: 0001676047

SIC: 3842 (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0285330-8k_nutriband.htm (Primary)

EX-99.1 — PRESS RELEASE ISSUED MARCH 30, 2026 (ea028533001ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0285330-8k_nutriband.htm · Sequence: 1

false

0001676047

2026-03-30

0001676047

us-gaap:CommonStockMember

2026-03-30

0001676047

NTRB:WarrantsMember

2026-03-30

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

SECURITIES

AND EXCHANGE COMMISSION

Washington,

DC 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of

the

Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported); March 30, 2026

Nutriband Inc.

Nevada

000-40854

81-1118176

(State

or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S.

Employer

Identification

No.)

121 S. Orange Ave. Suite 1500

Orlando,

Florida

32801

(Address

of Principal Executive Offices)

(Zip

Code)

(407)

377-6695

Registrant’s

Telephone Number, Including Area Code

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock

NTRB

The

Nasdaq Stock Market LLC

Warrants

NTRBW

The

Nasdaq Stock Market LLC

Item

7.01. Regulation FD Disclosure.

See

attached press release dated March 30, 2026.

Item

9.01 Financial Statements and Exhibits

(d)

Exhibits

The

following exhibits are being filed with this Current Report on Form 8-K:

99.1

Press Release issued March 30, 2026.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

PURSUANT

TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY

THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.

NUTRIBAND,

INC.

Date:

April

7, 2026

By:

/s/

Gareth Sheridan

Chief

Executive Officer

EX-99.1 — PRESS RELEASE ISSUED MARCH 30, 2026

EX-99.1

Filename: ea028533001ex99-1.htm · Sequence: 2

Exhibit

99.1

NUTRIBAND

SELECTS COMMERCIAL BRAND NAME FOR ITS ABUSE DETERRENT FENTANYL PATCH

Nutriband

has selected the commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit

to the FDA for approval per FDA Guidance.

Nutriband

partnered with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development.

ORLANDO,

FL / ACCESSWIRE / March 30, 2026 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal

pharmaceutical products, today announced that it has selected the commercial worldwide brand name candidate for its lead product, an

abuse deterrent fentanyl transdermal system. The proposed brand name and product labeling will be submitted to the FDA and other international

regulatory agencies for review and approval. In addition, the selected name is being submitted to the United States Patent and Trademark

Office for trademark registration and to secure full intellectual property rights in the United States and internationally.

The

company engaged Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development

services to develop the worldwide commercial brand name and visual identity for the product. This product utilizes Nutriband’s

AVERSA™ abuse deterrent transdermal technology and has the potential to be the world’s first abuse-deterrent patch designed

to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl.

Nutriband’s

abuse deterrent fentanyl transdermal system has the potential to reach peak annual US sales of $80 million to $200 million.1 While initially

concentrating on the US market, the unmet medical need for adequate pain management is a global problem, and the product is in development

for all major medical markets worldwide.

Developing

a proprietary brand name for a prescription drug product is a critical element in drug product development because the end users (doctors,

pharmacists, patients) must be able to easily distinguish a proprietary name from other drug names that are phonetically similar (sound-alike

names) or similar in their spelling or appearance (look-alike names). In addition, if the drug name is otherwise confusing or misleading,

the patient might receive the wrong product and the subsequent medication error could lead to significant harm to the patient.

Brand

Institute has been leading the market for over 20 years with a 75% share of drug name approvals globally, including 87% of FDA approved

names in 2024. In addition, Brand Institute has been responsible for many of the opioid chronic pain product brand names and specifically

a majority of the abuse deterrent opioid product brand names approved by FDA for sale in the United States.

Drug

Safety Institute (DSI), a wholly owned regulatory subsidiary of Brand Institute, will provide regulatory services, solutions and support

on the project. DSI is led by former officials from US Food & Drug Administration (FDA), European Medicines Agency (EMA), Health

Canada (HC), United States Adopted Name Council (USAN), and World Health Organization (WHO) who co-authored the naming guidance documents

while with their former respective agencies.

Nutriband’s

AVERSA™ abuse-deterrent technology is utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion,

misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse deterrent technology

is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States,

Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

Health

Advances Aversa Fentanyl market analysis report 2022

About

AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband’s

AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion,

misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve

the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible

to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in

the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About

Nutriband, Inc.

are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is

an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated

into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. The Company’s

website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part

of this press release.

About

Brand Institute, Inc., and wholly owned regulatory subsidiary, Drug Safety Institute Brand Institute is the global leader in pharmaceutical

and healthcare-related name development, with a portfolio of over 5,000 marketed healthcare brand names and 1,800 USAN/INN nonproprietary

names for nearly 1,600 clients. The company partners on over 75% of pharmaceutical brand and nonproprietary name approvals globally every

year with healthcare manufacturers. Drug Safety Institute is composed of former naming regulatory officials from global government health

agencies, including Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada (HC), American Medical Association

(AMA), and the World Health Organization (WHO). These regulatory experts co-authored the name review guidelines while with their former

respective agencies, with many responsible for ultimately approving (or rejecting) brand name applications to ensure safety and prevent

medication errors. To learn more about Brand Institute’s capabilities and experience, please visit www.brandinstitute.com and contact

your local Brand Institute representative.

Forward-Looking

Statements

Certain

statements contained in this press release, including, without limitation, statements containing the words ‘‘believes,”

“anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within

the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks

and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements

as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl

transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain

the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration

approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any

product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain,

manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development

plans;

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Mar. 30, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Mar. 30, 2026

Entity File Number

000-40854

Entity Registrant Name

Nutriband Inc.

Entity Central Index Key

0001676047

Entity Tax Identification Number

81-1118176

Entity Incorporation, State or Country Code

Entity Address, Address Line One

121 S. Orange Ave. Suite 1500

Entity Address, City or Town

Orlando

Entity Address, State or Province

Entity Address, Postal Zip Code

32801

City Area Code

407

Local Phone Number

377-6695

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock [Member]

Title of 12(b) Security

Common Stock

Trading Symbol

NTRB

Security Exchange Name

NASDAQ

Warrants

Title of 12(b) Security

Warrants

Trading Symbol

NTRBW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=NTRB_WarrantsMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: